Marco Meglio

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on care of trigeminal neuralgia.

The founder of the Stuttering Treatment and Research Society (STARS) discussed the unmet needs in stuttering care, current management strategies, and the mission of STARS to drive education, collaboration, and treatment development.

SKY-0515 shows promising results in reducing mutant huntingtin protein in Huntington disease patients, paving the way for transformative treatment options.

A groundbreaking study reveals the connection between GLP-1 hormones and brain inflammation in neuromyelitis optica spectrum disorder, suggesting new treatment avenues.

ShiraTronics reveals promising 12-month results from its neuromodulation device, showing significant migraine relief and improved quality of life for chronic migraine patients.

New research highlights daridorexant's effectiveness in improving sleep for women experiencing insomnia during menopause, showcasing significant benefits in sleep quality.

A recent trial reveals perispinal etanercept is safe for chronic stroke patients but shows no significant efficacy compared with placebo.

The vice chair of neurology at West Virginia University outlined key challenges in academic neurology and reflected on the evolving responsibilities of vice chairs in supporting departmental growth and leadership. [WATCH TIME: 3 minutes]

Novo Nordisk's semaglutide gains EU approval as the first oral GLP-1 RA to reduce cardiovascular risks in type 2 diabetes patients.

Avidity's del-zota shows promising results in reversing disease progression in Duchenne muscular dystrophy, paving the way for potential FDA approval.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on pre-surgical evaluation tools for epilepsy.

New guidelines enhance gene therapy delivery for Duchenne muscular dystrophy, emphasizing multidisciplinary care and safety monitoring for optimal patient outcomes.

Saol Therapeutics faces challenges after FDA's complete response letter for SL1009, a potential treatment for rare mitochondrial disorder PDCD.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Patricia Pozo-Rosich, MD, PhD. [LISTEN TIME: 19 minutes]

Tamara Kaplan, MD, vice chair of education for the department of neurology at Mass General Brigham, shares insights on evolving neurology education, highlighting her framework for supporting clinician educators and the growing recognition of education as a career path.

The vice chair of neurology at West Virginia University reflected on receiving the AUPN Leadership Award, addressing challenges in academic neurology and the evolving responsibilities of vice chairs in advancing departmental goals.

A recent study reveals dual orexin receptor agonists (DORAs) show significantly lower abuse potential compared to traditional insomnia medications.

Teva's emrusolmin receives FDA fast track designation as a potential breakthrough treatment for multiple system atrophy, targeting neurodegeneration.

The VP of clinical development at Alkermes detailed phase 2 results for alixorexton, an oral, selective orexin 2 receptor agonist, in narcolepsy type 1, including benefits for fatigue, cognition, and weakness.

Phase 3 trial results reveal EPX-100's safety and tolerability in Dravet syndrome, supporting its potential as an effective adjunctive therapy.

A recent trial shows that 3 infusions of stem cells significantly enhance motor function in Parkinson patients, highlighting the need for further research.

New trial data reveal claseprubart shows significant efficacy in treating generalized myasthenia gravis, paving the way for potential FDA approval.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on RNA therapeutics for neuromuscular disorders.

AL-S Pharma's AP-101 shows promising safety and efficacy in ALS patients, paving the way for future treatments targeting misfolded SOD1 proteins.

A recent study reveals that personalized extended interval dosing of natalizumab significantly reduces JCV seroconversion risk in patients with MS.

The head of the neurology department at Vall d’Hebron University Hospital provided perspective on how migraine treatment might advance in the near future, highlighting emerging pathways like PACAP antagonists and long-acting toxins. [WATCH TIME: 3 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Barry Byrne, MD, PhD. [LISTEN TIME: 15 minutes]

The laureate professor at the University of Melbourne detailed the design and promising results of the PACIFIC trial of bexicaserin, an agent in development for epileptic encephalopathies. [WATCH TIME: 4 minutes]

A recent study reveals GLP-1 receptor agonists significantly reduce medication use and symptoms in idiopathic intracranial hypertension patients, suggesting a promising management strategy.

Eisai and Biogen seek FDA approval for a convenient, at-home Alzheimer’s treatment option, enhancing patient flexibility and reducing costs.